Why Israel rocks at commercializing academic innovations
...abling investment in its biotech startups through the Tel Aviv Stock Exchange. HBL’s first exit was Cell Cure Neurosciences, in a $12.75 million deal with Biotime in June last year. “We’re now planning to raise another f...
Read Full Article